• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER Back to Search Results
Catalog Number 1BBWGQ506A2
Device Problems High Test Results (2457); Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 08/09/2022
Event Type  malfunction  
Event Description
The customer reported an elevated white blood cell (wbc) content in the whole blood product.Donor unit #: (b)(4) there was not a transfusion recipient or patient involved at the time of the unit processing, therefore no patient information is reasonably known at the time of the event.Terumo bct is awaiting return of the disposable set for evaluation.
 
Manufacturer Narrative
Investigation is in process.A follow up report will be provided.
 
Manufacturer Narrative
Corrected information is provided in b.6.Investigation: we received the collection bag with the leukocyte reduction filter, and the primary bag for investigation.The filter was rinsed with normal saline.The normal saline flowed relatively slow at a flow rate of 20 ml/min.We disassembled the rinsed filter to observe the appearance of filter media (membranes).We noticed creases in the filter media; however, the creases were not different from those observed in conforming products.We did not observe aggregates adhered to the filter media.An airtightness test was performed on the filter in accordance with the following procedures and we confirmed that air leaks were not observed in any locations of the filter.I) the tab sheet covering the outflow side (second side) of the filter is cut out carefully and exposed the outflow side to allow observing the frame sheet (partition) directly.Ii) air is admitted to the filter from the inflow-side tube at a gauge pressure of 39.2 kpa (0.4 kgf/cm2) for approximately 10 seconds in order to check whether there is any air leakage from the frame sheet (partition).After passing normal saline through the filter, we dyed the filter media with toluidine blue for observation and noticed that the first filter medium was dyed dark.That is, white blood cells were accumulated in these dyed areas.In regard to the production of imuflex, sealed bags are filled with solution and the line is assembled.These bags are sterilized, stacked, and placed into the blister packs.The top film of each blister pack is heat-sealed.For the leukoreduction filter, filter membranes are punched out, laminated, and integrated into soft housing.In order to ensure leukoreduction performance and to prevent filter occlusion in and hemolysis, standards have been set to control particulate removal rates and cationization levels of each filter membrane.The standards of average cationization levels of laminated filter membranes have also been set and controlled.We reviewed the manufacturing record of the lot number in question and confirmed that no anomalies occurred in any process, and the products were manufactured as usual.In addition, we investigated dope material used for the lot number in question and found that the viscosity of pu solution of dope material conformed to the standards.Release testing, which includes measurements of solution concentration and volume and a visual inspection, is performed on the product concerned on a sample basis.We reviewed each testing and inspection record of the production number and confirmed that there were no anomalies in all release testing items.The product conformed to the standards.Regarding the retained samples of the lot numbers in question, three sets each were visually examined.There were no abnormalities in their appearances.We used one set each to measure the solution volume and used another one set each to perform a quantitative test for the composition of the solution in the same manner as the release testing.The measured results conformed to our in-house standards.Root cause: we control to maintain cationization levels above a certain level during the production of filter media in order to prevent from wbc count failure (leukocyte leakage).Where a cationization level is high, filtration rate is likely to be low.For the prevention of wbc count failure, the instructions for use of the product state: "[caution] do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood", and ¿clamp the blood filled tubing before blood enters the filter¿.The above-mentioned investigation results revealed that there were no abnormalities in the manufacturing record and the testing and inspection record of the lot number concerned.The returned filter also revealed no abnormalities.We noticed that the first filter medium was dyed dark with toluidine blue.Therefore, occlusion may have occurred, and blood may have been filtered by the filter area which was smaller than usual, and the linear speed (flow rate per unit area) increased, and then wbc count failure (leukocyte leakage) occurred.
 
Event Description
The customer reported an elevated white blood cell (wbc) content in the whole blood product.Donor unit #: (b)(6) there was not a transfusion recipient or patient involved at the time of the unit processing, therefore no patient information is reasonably known at the time of the event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMUFLEX BLOOD BAG SYSTEM
Type of Device
IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER
Manufacturer (Section D)
TERUMO CORPORATION
fujinomiya 418-0 004
JA  418-0004
Manufacturer (Section G)
TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP
818 misonodaira
fujinomiya 418-0 004
JA   418-0004
Manufacturer Contact
makoto yoshikawa
818 misonodaira
fujinomiya 418-0-004
JA   418-0004
MDR Report Key15349677
MDR Text Key306160218
Report Number9681839-2022-00065
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 09/02/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/02/2022
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number1BBWGQ506A2
Device Lot Number211220AF
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/08/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-